
Opinion|Videos|January 13, 2025
Symptom Management Agents for Patients with Alzheimer’s Disease
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA issued a second complete response letter for deramiocel in Duchenne muscular dystrophy, citing insufficient evidence of effectiveness from the phase 3 HOPE-3 trial.

Chris Favilla, MD, stroke neurologist at the University of Pennsylvania, discusses findings that cerebral venous sinus stenting improves arterial hemodynamics in patients with idiopathic intracranial hypertension (IIH) and what they mean for understanding the disease.

5-year findings from the Clarity AD long-term extension, presented at CTAD 2026, showed progressively greater differences in CDR-SB outcomes compared with external natural history cohorts.

Mitzi Joi Williams, MD, is joined by Temitope Adeyey, MD, and Chantale Branson, MD, to discuss headache and facial pain conditions beyond migraine.

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Issues Second Complete Response Letter for Deramiocel in Duchenne Muscular Dystrophy
2
FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease
3
Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease
4
Pooled Review Finds No Benefit, More Bleeding With Distal Clot Removal
5


